| Business Summary | | Cortex
Pharmaceuticals,
Inc.
is
engaged
in
the
discovery,
development
and
commercialization
of
pharmaceuticals
for
the
treatment
of
neurodegenerative
diseases
and
other
neurological
and
psychiatric
disorders.
The
primary
effort
of
Cortex
is
centered
on
developing
products
that
affect
the
AMPA-type
glutamate
receptor,
a
complex
of
proteins
that
is
involved
in
most
"excitatory"
communication
between
nerve
cells
in
the
human
brain.
Cortex
is
developing
a
family
of
chemical
compounds,
known
as
Ampakines,
which
enhance
the
activity
of
this
receptor.
Cortex
believes
that
Ampakines
hold
promise
for
correcting
deficits
brought
on
by
a
variety
of
diseases
and
disorders
that
are
known,
or
thought,
to
involve
depressed
functioning
of
pathways
in
the
brain
that
use
glutamate
as
a
neurotransmitter. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | COR
is
a
development
stage
company
engaged
in
the
discovery,
development
and
commercialization
of
innovative
pharmaceuticals
for
the
treatment
of
neurological
and
psychiatric
disorders.
For
the
nine
months
ended
3/31/01,
revenues
rose
4%
to
$2.8
million.
Net
loss
rose
41%
to
$1.9
million.
Revenues
reflect
the
collaboration
agreement
with
Servier.
Earnings
were
offset
by
increased
research/development
expenses
and
stock
based
compensation
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Robert Allnutt, 65 Chairman | -- | -- | Vincent Simmon, Ph.D., 57 Pres,
CEO, Director | $295K | $113K | Maria Messinger, 33 CFO,
VP, Sec., Controller | 131K | -- | James Coleman Sr.
VP, Bus. Devel. | 166K | -- | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|